Healthcare Management in Cardio-Oncology, Clinical Strategies and Future Perspectives: A Narrative Review
Vincenzo Quagliariello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nicola Maurea(Cancer Institute (WIA)), Domenico Gabrielli(Azienda Ospedaliera San Camillo-Forlanini), Massimiliano Berretta(University of Messina), Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Celeste Fonderico(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alfredo Mauriello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Stefano Oliva(Istituto Tumori Bari), Matteo Barbato(University of Milan), Carmine Riccio(Ospedale Sant'Anna), Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Marino Scherillo, Fabrizio Maurea(Federico II University Hospital), Maria Laura Canale(Ospedale Versilia), Andrea Camerini(Ospedale Versilia)
Cited by 4
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108
Resveratrol in Cancer Patients: From Bench to Bedside
|International Journal of Molecular Sciences|2020|105